Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production

Translational Research

Volumn 161, Issue 6, 2013, Pages 477-485

  Moradi, Hamid ^a   Said, Hamid M ^a   Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; GLUCOSE; LUCIFERASE; MESSENGER RNA; PHOSPHORUS; POTASSIUM; SODIUM;

ARTICLE; BLOOD SAMPLING; CELL STRAIN HEPG2; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HEMODIALYSIS; HEPATOMA CELL; HUMAN; HUMAN CELL; KIDNEY FAILURE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; RNA STABILITY; UREA NITROGEN BLOOD LEVEL; UREMIA;

EID: 84878073451     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.11.001     Document Type: Article

References (56)

1. K/DOQI clinical practice for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S7 S266
2. Excerpts from the United States Renal Data system 2005 Annual Data Report. Atlas of end-stage renal disease in the United States Am J Kidney Dis 47 2006 S1 S286
3. Excerpts from the United States Renal Data system 2004 Annual Data Report. Atlas of end-stage renal disease in the United States Am J Kidney Dis 45 2005 S1 S280
4. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
5. N.D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences Am J Physiol 290 2006 262 272
6. N.D. Vaziri, and H. Moradi Mechanism of dyslipidemia of chronic renal failure Hemodialysis Int 10 2006 1 7 (Pubitemid 43263285)
7. N.D. Vaziri, M. Navab, and A.M. Fogelman HDL metabolism and activity in chronic kidney disease Nat Rev Nephrol 6 2010 287 296
8. N.D. Vaziri, H. Moradi, M.V. Pahl, A.M. Fogelman, and M. Navab In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide Kidney Int 76 2009 437 444
9. H. Moradi, J. Yuan, Z. Ni, K. Norris, and N.D. Vaziri Reverse cholesterol transport pathway in experimental chronic kidney disease Am J Nephrol 30 2009 147 154
10. H. Moradi, M.V. Pahl, R. Elahimehr, and N.D. Vaziri Impaired antioxidant activity of HDL in chronic kidney disease Transl Res 153 2009 77 85
11. N.D. Vaziri, K. Liang, and J.S. Parks Downregulation of hepatic lecithin: cholesterol acyltransferase (LCAT) gene expression in chronic renal failure Kidney Int 59 2001 2192 2196 (Pubitemid 32467611)
12. K. Liang, and N.D. Vaziri Upregulation of Acyl-CoA: cholesterol acyltransferase (ACAT) in chronic renal failure Am J Physiol 283 2002 E676 E681
13. M.V. Pahl, Z. Ni, L. Sepassi, and N.D. Vaziri Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease Nephrol Dial Transplant 24 2009 2541 2546
14. H.J. Kim, H. Moradi, and N.D. Vaziri Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney Am J Physiol 296 2009 F1297 F1306
15. H. Moradi, S. Ganji, Vj Kamanna, M.V. Pahl, and N.D. Vaziri Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease: response to antioxidant therapy Clin Nephrol 74 2010 273 281
16. N.D. Vaziri Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease J Ren Nutr 20 2010 S35 S43
17. N.D. Vaziri, and K. Norris Lipid disorders and their relevance to outcomes in chronic kidney disease Blood Purification 31 2011 189 196
18. M. Epstein, and N.D. Vaziri Role of statins in the management of dyslipidemia of chronic kidney disease: current concepts and emerging treatment paradigms Nat Rev Nephrol 8 2012 214 223
19. G.A. Kaysen Lipid and lipoprotein metabolism in chronic kidney disease J Ren Nutr 19 2009 73 77
20. G.A. Kaysen New insights into lipid metabolism in chronic kidney disease J Ren Nutr 21 2011 120 123
21. R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 2004 757 767
22. W.P. Casteli Cholesterol and lipids in the risk of coronary artery disease- the Framingham Study JAMA 256 1986 2835 2838
23. U. Goldbourt, J.S. Yaari, and J.H. Medalie Isolated low HDL cholesterol as a risk for coronary artery disease mortality: a 21-year follow-up of 8000 men Arterioscler Thromb Vasc Biol 17 1997 107 113 (Pubitemid 27057331)
24. M.J. Stampfer, F.M. Sacks, S. Salvin, W.C. Willet, and C.H. Hennekens A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N Engl J Med 325 1991 373 381
25. I. Shai, E.B. Rimm, and S.E. Hankinson Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines Circulation 110 2004 2824 2830 (Pubitemid 39473604)
26. G. Walldius, and I. Junger Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke Curr Opin Cardiol 22 2007 359 367 (Pubitemid 46897289)
27. D. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 2006 3090 3100 (Pubitemid 44878620)
28. L.W. Castellani, and A.J. Lusis ApoA-II versus ApoA-I: two for one is not always a good deal Arterioscler Thromb Vasc Biol 21 2001 1870 1872 (Pubitemid 34219734)
29. R. Williamson, D. Lee, J. Hagaman, and N. Maeda Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I Proc Natl. Acad Sci U S A 89 1992 7134 7138
30. E.J. Schaefer, W.H. Heaton, M.G. Wetzel, and H.B. Brewer Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease Arteriosclerosis 2 1982 16 26 (Pubitemid 12111016)
31. E. Rubin, R. Krauss, E. Spangler, J. Verstuyft, and S. Clift Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I Nature 353 1991 265 267 (Pubitemid 21896769)
32. A. Plump, C. Scott, and J. Breslow Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci U S A 91 1994 9607 9611 (Pubitemid 24297964)
33. R.K. Tangirala, K. Tsukamoto, S.H. Chun, D. Usher, E. Puré, and D.J. Rader Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice Circulation 100 1999 1816 1822 (Pubitemid 29498389)
34. P.O. Attman, P. Alaupovic, and A. Gustafson Serum apolipoprotein profile of patients with chronic renal failure Kidney Int 32 1987 368 375 (Pubitemid 17147883)
35. P.O. Attman, and P. Alaupovic Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis Nephron 57 1991 401 410
36. P. Muntner, L.L. Hamm, J.W. Kusek, J. Chen, P.K. Whelton, and J. He The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease Ann Intern Med 140 2004 9 17
37. P.O. Attman, and P. Alaupovic Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis Nephron 57 1991 401 410
38. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408 (Pubitemid 34164012)
39. Y.M. Yuen, and L.K. Leung Genistein and daidzein induced apoA-1 transactivation in hepG2 cells expressing oestrogen receptor-α Br J Nutr 99 2008 1007 1012
40. U.E.M. Gibson, C.A. Heid, and P.M. Williams A novel method for real-time quantitative RT-PCR Genome Res 6 1996 995 1001 (Pubitemid 26388092)
41. J.C. Reidling, S.M. Nabokina, and H.M. Said Molecular mechanisms involved in the adaptive regulation of human intestinal biotin uptake: a study of the hSMVT system Am J Physiol Gastrointest Liver Physiol 292 2007 G275 G281
42. M.C. Batista, F.K. Welty, and M.R. Diffenderfer Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome Metabolism 53 2004 1255 1261 (Pubitemid 39222084)
43. K. Okubo, K. Ikewaki, S. Sakai, N. Tada, Y. Kawaguchi, and S. Mochizuki Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study J Am Soc Nephrol 15 2004 1008 1015 (Pubitemid 38375319)
44. M.M. Fuh, C.M. Lee, and C.Y. Jeng Effect of chronic renal failure on high-density lipoprotein kinetics Kidney Int 37 1990 1295 1300 (Pubitemid 20148554)
45. V.S. Kamanna, M.L. Kashyap, and R. Pai Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line J Am Soc Nephrol 5 1994 193 200 (Pubitemid 24977075)
46. G.M. Shah, Z.L. Lin, and V.S. Kamanna Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism Kidney Int 50 1996 2079 2087 (Pubitemid 26417553)
47. N.D. Vaziri, G. Deng, and K. Liang Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure Nephrol Dial Transplant 14 1999 1462 1466 (Pubitemid 29241738)
48. M.J. Haas, M. Horani, A. Mreyoud, B. Plummer, N.C. Wong, and A.D. Mooradian Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta Biochim Biophys Acta 1623 2003 120 128 (Pubitemid 37315668)
49. Y.B. Park, S.K. Lee, and W.K. Lee Lipid profiles in untreated patients with rheumatoid arthritis J Rheumatol 26 1999 1701 1704 (Pubitemid 29367308)
50. S.S. Gidding, N.J. Stone, L.C. Bookstein, P.M. Laskarzewski, and E.A. Stein Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents J Pediatr 133 1998 242 246 (Pubitemid 28385202)
51. N.D. Vaziri Oxidative stress in chronic renal failure: the nature, mechanism and consequences Semin Nephrol 24 2004 469 473
52. N.D. Vaziri, Z. Ni, X.Q. Wang, F. Oveisi, and X.J. Zhou Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH Am J Physiol 274 1998 F642 F649
53. J. Himmelfarb, P. Stenvinkel, T.A. Ikizler, and R.M. Hakim The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 2002 1524 1538 (Pubitemid 35286260)
54. P.A. McCullough Why is chronic kidney disease the ''spoiler'' for cardiovascular outcomes? J Am Coll Cardiol 41 2003 725 728 (Pubitemid 36308376)
55. P. Stenvinkel, and A. Alvestrand Inflammation in end-stage renal disease: sources, consequences, and therapy Semin Dial 15 2002 329 337
56. M.J. Haas, N.C. Wong, and A.D. Mooradian Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells Metabolism 53 2004 766 771 (Pubitemid 38880909)